» Articles » PMID: 38543899

Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort

Overview
Date 2024 Mar 28
PMID 38543899
Authors
Affiliations
Soon will be listed here.
Abstract

The SARS-CoV-2 pandemic profoundly impacted people with multiple sclerosis (pwMS). Disease-related aspects and demographic factors may influence vaccination rates, infection susceptibility, and severity. Despite prior research, comprehensive real-world data obtained throughout the pandemic remain limited. We investigated SARS-CoV-2 vaccination and infection patterns in a large monocentric real-world cohort. We collected prospective data from medical visits at the MS Center Dresden, Germany, from the pandemic's beginning until 31 May 2022. Logistic regression and rank correlation analyses were used to explore associations between SARS-CoV-2 outcomes and patient characteristics. Of 2115 pwMS assessed (mean age 46.5, SD ± 12.9; median expanded disability status scale 2.5), 77.9% were under disease-modifying treatment (DMT), primarily B-cell depletion (25.4%). A total of 35.5% reported SARS-CoV-2 infections, and 77.4% were fully vaccinated. PwMS with increased disability, older age, and comorbidities were associated with higher vaccination rates, possibly due to the awareness of these populations regarding complications of SARS-CoV-2 infections. Infections were more common in younger females, people with a lower degree of disability, those with relapsing MS, and those who were not vaccinated. PwMS on B-cell depletion reported more infections than untreated pwMS and those receiving other types of disease-modifying therapy, despite higher vaccination rates. Most infections were mild, with no severity differences according to demographic or disease-related factors, except for gender. Notably, all fatal cases occurred in unvaccinated pwMS. Our studies suggest that demographic and disease-related factors, especially age and the use of B-cell depletion, significantly influenced SARS-CoV-2 vaccination and infection rates in our cohort. These factors may be considered in future preventive campaigns in further pandemics.

Citing Articles

SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma.

Al Rahbani G, Woopen C, Dunsche M, Proschmann U, Ziemssen T, Akgun K Vaccines (Basel). 2024; 12(6).

PMID: 38932415 PMC: 11209537. DOI: 10.3390/vaccines12060684.

References
1.
Pene F, Merlat A, Vabret A, Rozenberg F, Buzyn A, Dreyfus F . Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis. 2003; 37(7):929-32. PMC: 7107892. DOI: 10.1086/377612. View

2.
Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C . Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020; 77(9):1079-1088. PMC: 7320356. DOI: 10.1001/jamaneurol.2020.2581. View

3.
Salter A, Fox R, Newsome S, Halper J, Li D, Kanellis P . Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol. 2021; 78(6):699-708. PMC: 7980147. DOI: 10.1001/jamaneurol.2021.0688. View

4.
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P . Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021; 14:17562864211012835. PMC: 8072850. DOI: 10.1177/17562864211012835. View

5.
Richter D, Faissner S, Bartig D, Tonges L, Hellwig K, Ayzenberg I . Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany. Neurol Res Pract. 2021; 3(1):42. PMC: 8364944. DOI: 10.1186/s42466-021-00143-y. View